GTB-3650 TriKE®
Relapsed/Refractory CD33+ hematologic malignancies (Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome)
Key Facts
Indication
Relapsed/Refractory CD33+ hematologic malignancies (Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome)
Phase
Phase 1
Status
Active - Dose Escalation (Cohort 4 ongoing)
Company
About GT Biopharma
GT Biopharma is a micro-cap biotech focused on developing next-generation NK cell engagers via its proprietary TriKE® platform. The company's strategy centers on leveraging this modular technology to create potent, off-the-shelf immunotherapies that direct a patient's innate immune system against cancer. Key achievements include the ongoing Phase 1 trial for GTB-3650 in AML/MDS and the planned initiation of a Phase 1 trial for GTB-5550 in solid tumors in mid-2026. GT Biopharma's approach aims to differentiate from T-cell focused therapies by potentially offering a safer, more readily deployable treatment modality.
View full company profile